ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG (mIBG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01730417
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : November 21, 2012
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Molecular Insights Pharmaceuticals
Information provided by (Responsible Party):
Bennett Chin, Duke University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2011
  Actual Study Completion Date : July 2011
Publications of Results:
Chin BB, Grasfeder L, Femia F, Hillier S, Petry N, Armor T, Stubbs J, Stabin M, Babich J, Kronauge J. Phase 1 clinical trial results for high specific activity Ultratrace Iobenguane I 123. J Nucl Med. 2012;53:1516.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):